Here are the Form 4 insider transactions from ADARx Pharmaceuticals, Inc. (ADRX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ADRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADRX filings page.
ADARx Pharmaceuticals, Inc. director Erez Chimovits reported that OrbiMed Israel Partners II, L.P. purchased 61,516 common shares at $17 per share in the IPO on September 28, 2026. The entity’s Series A, Series B, Series B-1 and Series C preferred stock automatically converted into common stock at a 1-for-1.1717 ratio upon the IPO closing, without further consideration; each reported preferred-stock position was zero after conversion. OIP II held the securities directly. OrbiMed Advisors Israel II Limited exercised voting and investment power through a committee comprising Chimovits, Carl L. Gordon and David P. Bonita; all three disclaimed beneficial ownership, and Chimovits’s disclaimer was except to the extent of any pecuniary interest.
ADARx Pharmaceuticals, Inc. (ADRX) director and 10% owner Carl L. Gordon reported automatic conversion of preferred shares into 23,255,789 common shares upon the IPO closing. The shares were held directly by OrbiMed Private Investments VII, LP and OrbiMed Israel Partners II, L.P.; the conversion was on a 1-for-1.1717 basis without further consideration.
Those two entities and OrbiMed Genesis Master Fund, L.P. also purchased 950,000 common shares in the IPO on September 28, 2026, at $17 per share: 300,249, 61,516, and 588,235 shares, respectively. Gordon disclaims beneficial ownership of the reported securities except to the extent of any pecuniary interest.
ADARx Pharmaceuticals, Inc. (ADRX) had Preferred Stock held by OrbiMed-affiliated funds automatically converted into common shares upon the closing of its initial public offering on September 28, 2026, on a 1-for-1.1717 basis and without further consideration.
In the IPO, OrbiMed Private Investments VII, LP purchased 300,249 shares, OrbiMed Israel Partners II, L.P. purchased 61,516 shares, and OrbiMed Genesis Master Fund, L.P. purchased 588,235 shares, each at $17 per share. The shares were held directly by those funds, while related OrbiMed general partners and advisers reported indirect ownership. The footnotes identify Carl L. Gordon, W. Carter Neild, Geoffrey C. Hsu, David P. Bonita and Erez Chimovits as members of the applicable management committees and state that they disclaim beneficial ownership of the relevant fund shares. No Rule 10b5-1 plan is reported.
ADARx Pharmaceuticals, Inc. had indirect preferred-stock conversions reported by SR One Capital Management, LLC, a ten percent owner. The preferred securities were directly held by SR One Capital Fund I Aggregator, LP, SR One Capital Opportunities Fund I, LP and SR One Co-Invest III, LLC; upon ADARx’s IPO closing on September 28, 2026, they automatically converted into common stock on a 1-for-1.1717 reverse stock split basis, without further consideration. Separately, SR One Capital Fund I Aggregator, LP purchased 592,593 shares, SR One Capital Opportunities Fund I, LP purchased 414,814 shares and AMZL, LP purchased 592,593 shares, each at $17 per share. AMZL held 592,593 shares after its purchase. No Rule 10b5-1 plan is reported.
ADARx Pharmaceuticals, Inc. (ADRX) reports preferred-stock conversions and common-stock purchases on September 28, 2026, through entities associated with Simeon George, identified as a director and 10% owner. The conversions produced 3,334,938 and 1,113,666 common shares for SR One Capital Fund I Aggregator, LP; 1,538,691 for SR One Capital Opportunities Fund I, LP; and 1,667,468 and 169,001 for SR One Co-Invest III, LLC. Each preferred-stock derivative entry showed zero shares following conversion.
SR One Capital Fund I Aggregator, LP purchased 592,593 shares, SR One Capital Opportunities Fund I, LP purchased 414,814 shares, and AMZL, LP purchased 592,593 shares, each at $17.00 per share; AMZL, LP reported 592,593 shares following its purchase. The preferred shares automatically converted upon the IPO closing, without further consideration, on a 1-for-1.1717 reverse stock split basis. Transactions were indirect and attributed to the named entities; George disclaimed beneficial ownership of portions in which he had no pecuniary interest.
ADARx Pharmaceuticals, Inc. (ADRX) reported that LAV Biosciences Fund V, L.P., LAV Fund VI, L.P. and LAV Fund VI Opportunities, L.P.—each identified as a ten-percent owner—converted preferred stock into common stock on September 28, 2026, upon closing of the company’s IPO. The preferred stock converted automatically on a 1-for-1.1717 reverse stock split basis, without payment of further consideration.
LAV Biosciences Fund V converted 10,438,412 Series A, 1,953,774 Series B, 601,161 Series B-1 and 180,288 Series C preferred shares into 8,908,775, 1,667,469, 513,067 and 153,868 common shares, respectively. LAV Fund VI and LAV Fund VI Opportunities each converted 360,577 Series C preferred shares into 307,738 common shares.
ADARx Pharmaceuticals, Inc. Chief Technology Officer Rui (NMN) Zhu received an award of employee stock options covering 512,076 shares of common stock on September 24, 2026. The options have a $17 per-share exercise price and expire September 23, 2036. One-quarter vests and becomes exercisable on September 24, 2027; the remainder vests and becomes exercisable in equal quarterly installments thereafter over three years, subject to Zhu's continued service on each vesting date.
ADARx Pharmaceuticals, Inc. Chief Scientific Officer Alan Robert MacLeod was granted employee stock options covering 170,692 common shares on September 24, 2026, at an exercise price of $17 per share. One-fourth of the shares vest and become exercisable on September 24, 2027; the remaining shares vest in equal quarterly installments thereafter over a three-year period, subject to his continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. reported that CFO and CBO Ryan Fisk received a direct grant of options covering 170,692 common shares on September 24, 2026, with a $17 exercise price. One-fourth of the shares vest and become exercisable on September 24, 2027; the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to his continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. President and CEO Zhen Li received an employee stock option award covering 1,024,152 common shares on September 24, 2026, with an exercise price of $17.00 per share. One-fourth vests and becomes exercisable on September 24, 2027; the remaining shares vest and become exercisable in equal quarterly installments thereafter over a three-year period, subject to continued service on each vesting date. The options expire September 23, 2036.
ADARx Pharmaceuticals, Inc. Chief People Officer Robert William Ackles received an employee stock option award covering 85,346 shares, with an exercise price of $17.00 per share. One quarter vests and becomes exercisable on September 24, 2027; the remaining options vest in equal quarterly installments over three years, subject to his continued service on each vesting date. The options expire September 23, 2036.